RFRoger A. Fielding

Roger A. Fielding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roger A. Fielding has a total of 407 co-authors. Here are the top co-authors by number of shared publications:

  • Edward M. Phillips

    Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts; and

    15 shared publications
  • Kieran F. Reid

    Tufts University, Boston, Massachusetts (K.F.R., R.A.F.)

    9 shared publications
  • Donato Americo Rivas

    Tufts University

    8 shared publications
  • David J. Clark

    Brain Rehabilitation Research Center, Malcom Randall VA Medical Center and Department of Aging and Geriatric Research, University of Florida, Gainesville

    7 shared publications
  • Michael S. Lustgarten

    Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts; and 2Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts

    7 shared publications
  • Anne B. Newman

    Department of Epidemiology, School of Public Health, University of Pittsburgh , Pittsburgh, Pennsylvania

    6 shared publications

Latest Publications

  • Open Access

    Metabolomic Signatures of Physical Function and Functional Trajectories in Older Adults: Insights from the ENRGISE Clinical Trial

    by David H. Lynch, Liubov Arbeeva, Susan C. J. Sumner, Blake R. Rushing, John A. Batsis, Amanda E. Nelson, Roger A. Fielding

    Background: Chronic inflammation contributes to functional decline in older adults, yet interventions targeting inflammatory pathways have shown inconsistent results. Metabolomics offers a promising approach to identify biological heterogeneity and uncover molecular signatures underlying differential functional trajectories. Objective: Our objective was to examine whether untargeted serum metabolomics can identify metabolic signatures associated with baseline physical function, functional trajectories, and treatment response in older adults with chronic inflammation participating in the ENRGISE trial. Methods: We performed untargeted metabolomic profiling on serum samples (n = 731) collected at baseline, 6, and 12 months from participants (mean age ≥ 70) enrolled in the ENRGISE pilot randomized trial. Participants were randomized to losartan, omega-3 supplementation, both, or placebo. Functional measures included grip strength and 400 m gait speed. Group-based trajectory modeling classified participants into functional trajectories over 12 months. Partial least squares-discriminant analysis (PLS-DA) and pathway enrichment (mummichog algorithm) were used to identify differentially abundant metabolites and perturbed pathways. Results: Baseline metabolomic profiles differed by physical function status. Participants with low grip strength showed enrichment in vitamin A metabolism pathways, while slower gait speed was associated with higher levels of prostaglandin and eicosanoid metabolites. Baseline metabolic profiles distinguished individuals who later declined versus improved in functional performance. Omega-3 supplementation, but not losartan, induced distinct changes in lipid-related pathways, including fatty acid activation, omega-3 metabolism, and prostaglandin biosynthesis, indicating that individuals responded to these interventions metabolically despite null clinical outcomes. Conclusions: Serum metabolomic signatures were associated with baseline physical function, predicted functional trajectories, and revealed pharmacologic activity of omega-3 supplementation. These findings support the use of metabolomics to uncover biological heterogeneity and inform precision geroscience strategies in aging populations.


  • Open Access

    Psychometric Properties of the SarQoL Questionnaire: A Systematic Review and Meta‐Analysis

    by Céline Demonceau, Brabant Christian, Shukuru Emmanuel, Majed Alokail, Nasser Al‐Daghri, Yves Rolland, Ivan Bautmans, Jürgen M. Bauer, Antonio Cherubini, Alfonso J. Cruz‐Jentoft, et al.

    Background: The Sarcopenia and Quality of Life (SarQoL) questionnaire is recognized as the only disease‐specific patient‐reported outcome measure (PROM) for assessing sarcopenia‐related HRQoL. This systematic review and meta‐analysis aimed to provide a quantitative summary of all evidence reported on the reliability, validity, responsiveness and floor/ceiling effects of SarQoL in older adults. Methods: Following PRISMA‐COSMIN guidelines, a systematic search for studies evaluating the psychometric properties of SarQoL (i.e., reliability, validity, responsiveness and floor and ceiling effects) in older people was conducted on MEDLINE (via OVID), PsycINFO, Scopus and EMBASE. Studies published between 2013 and November 2024 using a consensual definition of sarcopenia were included. Study selection and data extraction were made by two independent reviewers. A random‐effects model meta‐analysis was applied. PROSPERO registration: CRD42024546880. Results: From 411 studies identified by the search strategy, 25 fulfilled the inclusion criteria, including 4585 community‐dwelling individuals, of which 1311 were diagnosed as sarcopenic. SarQoL demonstrated high reliability (pooled Cronbach's alpha values consistently exceeding 0.80) and excellent test–retest reliability (pooled ICC = 0.98). Construct validity was confirmed with strong convergent correlations (pooled r > 0.54) with related dimensions of generic SF‐36 and EQ‐5D and weaker divergent correlations (pooled r < 0.47). Responsiveness, evaluated in two studies using different methodologies, supported the ability of SarQoL to detect meaningful changes in HRQoL. The certainty of evidence was rated as high for reliability, validity and responsiveness. Conclusion: This meta‐analysis consolidates a decade of evidence and confirms the strong psychometric properties of SarQoL, with a high level of evidence.


  • Open Access

    Identifying Older Adults at Risk of Accelerated Decline in Gait Speed and Grip Strength: Insights from the National Health and Aging Trends Study (NHATS)

    by David H. Lynch, Hillary Spangler, Jacob S. Griffin, Anna Kahkoska, Dominic Boccaccio, Wenyi Xie, Feng-Chang Lin, John A. Batsis, Roger A. Fielding

    Gait speed and grip strength are widely used measures of physical function in older adults and are predictive of disability, hospitalization, and mortality. However, there is a limited understanding of the long-term trajectories of these measures and which older adults are at the highest risk of functional decline. We used data from the National Health and Aging Trends Study (NHATS) to identify subgroups of community-dwelling older adults with distinct 10-year trajectories in gait speed and grip strength and to examine the baseline factors associated with these patterns. The sample included 4961 adults aged 65 years and older who completed gait speed and grip strength assessments in 2011 and at least one subsequent wave between 2013 and 2021. Using latent class growth analysis, we identified three trajectories for each measure: worsening, stable, and improving. More than one-third of participants were in the worsening group for at least one measure. In multinomial logistic regression models, lower income, Medicaid coverage, cognitive impairment, and multiple chronic conditions were associated with membership in worsening trajectory groups. These findings highlight the heterogeneity of physical aging and the importance of the early identification of older adults who may benefit from targeted interventions to maintain function and independence over time.


  • Open Access

    Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study

    by Michelle M. Mielke, Roger A. Fielding, Elizabeth J. Atkinson, Zaira Aversa, Marissa J. Schafer, Steven R. Cummings, Marco Pahor, Christiaan Leeuwenburgh, Nathan K. LeBrasseur


  • Open Access

    Predictive value of sarcopenia components for all-cause mortality: findings from population-based cohorts

    by Leo D. Westbury, Nicholas C. Harvey, Charlotte Beaudart, Olivier Bruyère, Jane A. Cauley, Peggy Cawthon, Alfonso J. Cruz-Jentoft, Elizabeth M. Curtis, Kristine Ensrud, Roger A. Fielding, et al.

    Background: Low grip strength and gait speed are associated with mortality. However, investigation of the additional mortality risk explained by these measures, over and above other factors, is limited. Aim: We examined whether grip strength and gait speed improve discriminative capacity for mortality over and above more readily obtainable clinical risk factors. Methods: Participants from the Health, Aging and Body Composition Study, Osteoporotic Fractures in Men Study, and the Hertfordshire Cohort Study were analysed. Appendicular lean mass (ALM) was ascertained using DXA; muscle strength by grip dynamometry; and usual gait speed over 2.4–6 m. Verified deaths were recorded. Associations between sarcopenia components and mortality were examined using Cox regression with cohort as a random effect; discriminative capacity was assessed using Harrell’s Concordance Index (C-index). Results: Mean (SD) age of participants (n = 8362) was 73.8(5.1) years; 5231(62.6%) died during a median follow-up time of 13.3 years. Grip strength (hazard ratio (95% CI) per SD decrease: 1.14 (1.10,1.19)) and gait speed (1.21 (1.17,1.26)), but not ALM index (1.01 (0.95,1.06)), were associated with mortality in mutually-adjusted models after accounting for age, sex, BMI, smoking status, alcohol consumption, physical activity, ethnicity, education, history of fractures and falls, femoral neck bone mineral density (BMD), self-rated health, cognitive function and number of comorbidities. However, a model containing only age and sex as exposures gave a C-index (95% CI) of 0.65(0.64,0.66), which only increased to 0.67(0.67,0.68) after inclusion of grip strength and gait speed. Conclusions: Grip strength and gait speed may generate only modest adjunctive risk information for mortality compared with other more readily obtainable risk factors.


  • Open Access

    Impact of a Whole-Food, High-Soluble Fiber Diet on the Gut–Muscle Axis in Aged Mice

    by Roger A. Fielding, Michael S. Lustgarten

    Previous studies have identified a role for the gut microbiome and its metabolic products, short-chain fatty acids (SCFAs), in the maintenance of muscle mass and physical function (i.e., the gut–muscle axis), but interventions aimed at positively impacting the gut–muscle axis during aging are sparse. Gut bacteria ferment soluble fiber into SCFAs, and accordingly, to evaluate the impact of a high-soluble-fiber diet (HSFD) on the gut–muscle axis, we fed a whole-food, 3×-higher-soluble fiber-containing diet (relative to standard chow) to aged (98 weeks) C57BL/6J mice for 10 weeks. The HSFD significantly altered gut bacterial community structure and composition, but plasma SCFAs were not different, and a positive impact on muscle-related measures (when normalized to body weight) was not identified. However, when evaluating sex differences between dietary groups, female (but not male) HSFD-fed mice had significant increases for SCFAs, the quadriceps/body weight (BW) ratio, and treadmill work performance (distance run × BW), which suggests that an HSFD can positively impact the gut–muscle axis. In contrast, consistent effects in both male and female HSFD-fed mice included weight and fat loss, which suggests a positive role for an HSFD on the gut–adipose axis in aged mice.


  • Top Cited Papers
    Open Access

    The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS)

    by Ben Ben Kirk, Peggy M Cawthon, Hidenori Arai, José A Ávila-Funes, Rocco Barazzoni, Shalender Bhasin, Ellen F Binder, Olivier Bruyere, Tommy Cederholm, Liang-Kung Chen, et al.

    Importance: Sarcopenia, the age-related loss of muscle mass and strength/function, is an important clinical condition. However, no international consensus on the definition exists. Objective: The Global Leadership Initiative in Sarcopenia (GLIS) aimed to address this by establishing the global conceptual definition of sarcopenia. Design: The GLIS steering committee was formed in 2019–21 with representatives from all relevant scientific societies worldwide. During this time, the steering committee developed a set of statements on the topic and invited members from these societies to participate in a two-phase International Delphi Study. Between 2022 and 2023, participants ranked their agreement with a set of statements using an online survey tool (SurveyMonkey). Statements were categorised based on predefined thresholds: strong agreement (>80%), moderate agreement (70–80%) and low agreement (<70%). Statements with strong agreement were accepted, statements with low agreement were rejected and those with moderate agreement were reintroduced until consensus was reached. Results: 107 participants (mean age: 54 ± 12 years [1 missing age], 64% men) from 29 countries across 7 continents/regions completed the Delphi survey. Twenty statements were found to have a strong agreement. These included; 6 statements on ‘general aspects of sarcopenia’ (strongest agreement: the prevalence of sarcopenia increases with age (98.3%)), 3 statements on ‘components of sarcopenia’ (muscle mass (89.4%), muscle strength (93.1%) and muscle-specific strength (80.8%) should all be a part of the conceptual definition of sarcopenia)) and 11 statements on ‘outcomes of sarcopenia’ (strongest agreement: sarcopenia increases the risk of impaired physical performance (97.9%)). A key finding of the Delphi survey was that muscle mass, muscle strength and muscle-specific strength were all accepted as ‘components of sarcopenia’, whereas impaired physical performance was accepted as an ‘outcome’ rather than a ‘component’ of sarcopenia. Conclusion and relevance: The GLIS has created the first global conceptual definition of sarcopenia, which will now serve to develop an operational definition for clinical and research settings.


  • A Critical Review of Current Worldwide Definitions of Sarcopenia

    by Haya F. Alhmly, Roger A. Fielding

    With the increasing number of elderly individuals worldwide, the prevalence of age-related loss of muscle mass, referred to as sarcopenia, is expected to increase. Sarcopenia is a relatively new recognized syndrome, which is thought to affect 13% individuals worldwide, and the significant efforts made by different groups have advanced our understanding of the diagnosis, treatment, and natural history of this condition. However, the challenge is now to standardize its measurement and diagnosis to facilitate research in this area and a greater understanding of this condition and its management between clinicians and researchers. The Global Leadership Initiative on Sarcopenia (GLIS) is at the forefront of an international effort to produce standardized definition of sarcopenia. Setting a definition for sarcopenia entails several considerations and trade-offs. In this critical review, we have addressed key challenges driving the process of standardizing the definition, while delving into future avenues in sarcopenia research. Establishing a clear consensus on the working definition of sarcopenia is essential not only for advancing research in this field but also for assessing the prognostic implications of diagnosing sarcopenia and determining the most suitable treatment for affected patients.